Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Claire Fritz, Scott M. Portwood, MS, MBA, Julie Adams, BS, Tara Cronin, BA, Linda Lutgen-Dunckley, Brandon L Martens, BS, Callum M. Sloss, PhD, Krystal Watkins, Yelena Kovtun, PhD, Sharlene Adams, PhD, Eunice S. Wang, MD

Blood (2018) 132 (Supplement 1): 2647.

https://doi.org/10.1182/blood-2018-99-117214

Published: 2018

Journal Articles

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Blood (2018) 132 (Supplement 1): 769.

https://doi.org/10.1182/blood-2018-99-118047

Published: 2018

Journal Articles

Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms

Margaret Nieborowska-Skorska, Silvia Maifrede, Yashodhara Dasgupta, Katherine Sullivan, Bac Viet Le, Martyna Solecka, Lucia Kubovcakova, Morgan Nawrocki, Martin Kirschner, MD, Huaqing Zhao, Josef T. Prchal, MD, Katarzyna Piwocka, Alison R. Moliterno, MD, Steffen Koschmieder, Anthony R Green, PhD FRCP, FRCPath, FMedSci, Radek C. Skoda, MD, Tomasz Skorski

Blood (2017) 130 (Supplement 1): 2938.

https://doi.org/10.1182/blood.V130.Suppl_1.2938.2938

Published: 2017

Journal Articles

Mutations in Cohesin Complex As Potential Targets for Therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome

Nazia Matto, Terry J Gaymes, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Syed A Mian, BSc, M.Phil, Ghulam J Mufti, FRCP, FRCPath

Blood (2015) 126 (23): 1221.

https://doi.org/10.1182/blood.V126.23.1221.1221

Published: 2015

Journal Articles

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Xiaohui Zhang, MD, PhD, Jing Lu, PhD, Yimin Qian, PhD, Robert Z. Orlowski, PhD, MD

Blood (2015) 126 (23): 917.

https://doi.org/10.1182/blood.V126.23.917.917

Published: 2015

Journal Articles

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2013) 122 (21): 1978.

https://doi.org/10.1182/blood.V122.21.1978.1978

Published: 2013

Journal Articles

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

Paola Neri, MD, PhD, Peter Duggan, MD, FRCPC, Kathy Gratton, Li Ren, PhD, Jordan Johnson, Jiri Slaby, MD, Douglas A. Stewart, MD, FRCP, Jonathan J Keats, PhD, Nizar J. Bahlis, MD

Blood (2012) 120 (21): 1862.

https://doi.org/10.1182/blood.V120.21.1862.1862

Published: 2012

Journal Articles

JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL)

Changhong Yin, MS, Sanghoon Lee, PhD, MSc, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, James Pao, BA, Erin Mulvey, BA, Mitchell S. Cairo, MD

Blood (2012) 120 (21): 4886.

https://doi.org/10.1182/blood.V120.21.4886.4886

Published: 2012

Journal Articles

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Paola Neri, MD, PhD, Li Ren, PhD, Kathy Gratton, Erin Stebner, Carolyn J Owen, MD, FRCPC, Peter Duggan, MD, FRCPC, Adnan Mansoor, MD, FCPS, FRCP(C), FCAP, Douglas A. Stewart, MD, FRCP, Nizar J Bahlis, MD

Blood (2010) 116 (21): 789.

https://doi.org/10.1182/blood.V116.21.789.789

Published: 2010

Journal Articles

Nicotinamide Promotes Apoptosis In Chronic Lymphocytic Leukemia through Activation of the p53/Mir-34a/SIRT1 Tumor Suppressor Network

Valentina Audrito, Tiziana Vaisitti, Sara Serra, Davide Rossi, Daniela Gottardi, Giovanni D’Arena, Gianluca Gaidano, Fabio Malavasi, Silvia Deaglio

Blood (2010) 116 (21): 4627.

https://doi.org/10.1182/blood.V116.21.4627.4627

Published: 2010

Journal Articles

Histone Deacetylase Inhibitors Promote Abnormal Binding of DNA Repair Proteins to DNA Double Strand Breaks: Consequences for DNA Repair and Genomic Instability?.

Carine Robert, PhD, Ivana Gojo, MD, Feyruz V. Rassool, PhD

Blood (2009) 114 (22): 186.

https://doi.org/10.1182/blood.V114.22.186.186

Published: 2009

Journal Articles

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

Hua Yan, Dao Li, Li Chen, Ying-Li Wu, Jun-Ming Li, Guo-Qiang Chen

Blood (2008) 112 (11): 4233.

https://doi.org/10.1182/blood.V112.11.4233.4233

Published: 2008

Journal Articles

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

Deborah J. Kuhn, PhD, Qing Chen, PhD, Peter M. Voorhees, MD, John S. Strader, Kevin D. Shenk, PhD, Congcong M. Sun, PhD, Susan D. Demo, PhD, Mark K. Bennett, PhD, Fred W. van Leeuwen, PhD, Robert Z. Orlowski, MD, PhD

Blood (2006) 108 (11): 3461.

https://doi.org/10.1182/blood.V108.11.3461.3461

Published: 2006

Journal Articles

R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.

Hiroshi Yasui, Teru Hideshima, Paola Neri, Janice Jin, Tanyel Kiziltepe, Norihiko Shiraishi, Kenji Ishitsuka, Catley P. Laurence, Noopur Raje, Klaus Podar, Pierfrancesco Tassone, Dharminder Chauhan, Paul G. Richardson, Lorenzo M. Leoni, Sarath Kanekal, Gary T. Elliott, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2005) 106 (11): 1580.

https://doi.org/10.1182/blood.V106.11.1580.1580

Published: 2005

NARROW

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Synergistic Anti-Leukemic Activity of PARP Inhibition Combined with IMGN632, an Anti-CD123 Antibody-Drug Conjugate in Acute Myeloid Leukemia Models

Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion

Ruxolitinib-Induced Defects in DNA Repair Cause Sensitivity to PARP Inhibitors in Myeloproliferative Neoplasms

Mutations in Cohesin Complex As Potential Targets for Therapeutic Intervention By PARP (Poly ADP Ribose Polymerase) Inhibitors in Myelodysplastic Syndrome

Proteolytic Targeting Chimeric Molecules (PROTACs) Specific for Bromodomain-Containing Protein (BRD) 4 Are Active Against Pre-Clinical Models of Multiple Myeloma

Outcomes and Correlative Studies Of a Phase I Trial With The Oral PARP1-2 Inhibitor Veliparib In Combination With Bortezomib In Patients With Relapsed Or Refractory Multiple Myeloma

Phase I Study of the PARP1-2 Inhibitor Veliparib in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

JAK1/JAK2 Inhibitor, Ruxolitinib Inhibits Cell Proliferation and Induces Apoptosis in Hodgkin Lymphomas (HL) and Primary Mediastinal B-Cell Lymphomas (PMBL)

Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors

Nicotinamide Promotes Apoptosis In Chronic Lymphocytic Leukemia through Activation of the p53/Mir-34a/SIRT1 Tumor Suppressor Network

Histone Deacetylase Inhibitors Promote Abnormal Binding of DNA Repair Proteins to DNA Double Strand Breaks: Consequences for DNA Repair and Genomic Instability?.

Synergistically Cooperation of Bortezomib and Arsenic Trioxide on Chronic Myelogenous Leukemia

The Novel, Irreversible Proteasome Inhibitor PR-171 Demonstrates Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma, and Overcomes Bortezomib Resistance.

R-Etodolac and a Novel Indole-Pyran Structural Analog, SDX-308, Induce Cytotoxicity and Overcome Drug Resistance in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only